Lexicon Pharmaceuticals - About the company
Lexicon Pharmaceuticals is a public company based in The Woodlands (United States), founded in 1995. It operates as a Developer of small molecule drugs for diffrent health diseases. Lexicon Pharmaceuticals has raised an undisclosed amount in funding. The company has 314 active competitors, including 113 funded and 61 that have exited. Its top competitors include companies like Sana Biotechnology, Metabolon and Semma Therapeutics.
Company Details
Developer of small molecule drugs for diffrent health diseases. The company uses gene trapping and gene targeting technologies to discover new drug targets and develop small molecule drugs across therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
- Website
- Social
Key Metrics
Founded Year
1995
Location
The Woodlands, United States
Stage
Public
Latest Funding Round
Investors
Ranked
22nd among 314 active competitors
Annual Revenue
as on Dec 31, 2022
Employee Count
as on Feb 28, 2023
Similar Companies
Exit Details
Public
Legal entities associated with Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is associated with 4 legal entities given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
$1M - $5M (as on Aug 07, 2012) | 974 | 740 | ||
Oct 26, 2016 | - | 499 | 475 | |
Apr 06, 2000 | - | 790 | 651 | |
Jul 06, 1995 | $139K (as on Dec 31, 2022) | 387 | 258 |
Get your free copy of Lexicon Pharmaceuticals's company profile
Lexicon Pharmaceuticals's funding and investors
Lexicon Pharmaceuticals has raised funding over 8 rounds. Its first funding round was on May 1998.
Lexicon Pharmaceuticals has 4 institutional investors including New Enterprise Associates, Bay City Capital and .
Here is the list of recent funding rounds of Lexicon Pharmaceuticals:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Aug 03, 2022 | $42.9M | Post IPO | 8601242 | 1721296 | - |
Mar 24, 2017 | $10.5M | Post IPO | 9429158 | 7271866 | - |
Dec 12, 2014 | $4.66M | Post IPO | 6422594 | 8588161 | - |
Access funding benchmarks and valuations. Sign up today!View details of Lexicon Pharmaceuticals's funding rounds and investors
Lexicon Pharmaceuticals's founders and board of directors
Lexicon Pharmaceuticals's employee count trend
Lexicon Pharmaceuticals has 135 employees as of Feb 23. The total employee count is 55.2% more than what it was in Feb 22. Here is Lexicon Pharmaceuticals's employee count trend over the years:
Uncover Lexicon Pharmaceuticals's growth story! Sign up today!Lexicon Pharmaceuticals's Competitors and alternates
Top competitors of Lexicon Pharmaceuticals include Sana Biotechnology, Metabolon and Semma Therapeutics. Here is the list of Top 10 competitors of Lexicon Pharmaceuticals, ranked by ÃØÃÜÑо¿Ëù score :
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | ÃØÃÜÑо¿Ëù Score |
|---|---|---|---|---|---|
1st |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | CPP Investments, Omega FundsÌý&²¹³¾±è;Ìý | 72/100 |
2nd | Metabolon 2000, Morrisville (United States), Series H | Provider of solutions for biomarker discovery, diagnostic tests and personalized medicine | $181M | EW Healthcare Partners, Perceptive AdvisorsÌý&²¹³¾±è;Ìý | 72/100 |
3rd | Semma Therapeutics 2015, Cambridge (United States), Acquired | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | $158M | Arch Venture Partners, F-Prime CapitalÌý&²¹³¾±è;Ìý | 72/100 |
4th | Developer of therapeutics for the treatment of diabetes and obesity | $26M | Idinvest Partners, BpifranceÌý&²¹³¾±è;Ìý | 70/100 | |
5th | Maze Therapeutics 2018, Redwood City (United States), Public | Developer of genetic bio-markers in neurological, metabolic, and renal diseases | $496M | Foresite Capital, Arch Venture PartnersÌý&²¹³¾±è;Ìý | 71/100 |
6th |  Alector 2013, San Francisco (United States), Public | Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders | $215M | New Leaf Venture Partners, Foresite CapitalÌý&²¹³¾±è;Ìý | 70/100 |
7th | Rezolute 2012, Denver (United States), Public | Biopharmaceutical company developing therapies for metabolic & orphan diseases | - | Bay City Capital, CitadelÌý&²¹³¾±è;Ìý | 68/100 |
8th | Cellino 2017, Cambridge (United States), Series A | Developer of autologous cell therapies | $125M | Felicis Ventures, Khosla VenturesÌý&²¹³¾±è;Ìý | 68/100 |
9th | Seer 2017, San Francisco (United States), Public | Developer of proteomics platform for early detection of cancer and neurological diseases | $128M | T. Rowe Price, HBM Healthcare InvestmentsÌý&²¹³¾±è;Ìý | 67/100 |
10th |  Tango Therapeutics 2017, Cambridge (United States), Public | Developer of drugs for the treatment of cancer | $165M | Third Rock Ventures, Casdin CapitalÌý&²¹³¾±è;Ìý | 66/100 |
22nd | 1995, The Woodlands (United States), Public | Developer of small molecule drugs for diffrent health diseases | - | New Enterprise Associates, Bay City CapitalÌý&²¹³¾±è;Ìý | 53/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Lexicon Pharmaceuticals's competitors? Click to see the top ones
Lexicon Pharmaceuticals's Investments and acquisitions
Lexicon Pharmaceuticals has made no investments or acquisitions yet.
Reports related to Lexicon Pharmaceuticals
Here is the latest report on Lexicon Pharmaceuticals's sector:
View
News related to Lexicon Pharmaceuticals
Media has covered Lexicon Pharmaceuticals for a total of 42 events in the last 1 year, 16 of them have been about company updates and 12 about people movement.
•
•
•
•
GlobeNewswire•Mar 03, 2025•Lexicon Pharmaceuticals
•
BioSpace•Mar 03, 2025•Lexicon Pharmaceuticals
•
•
•
Seeking Alpha•Dec 20, 2024•Lexicon Pharmaceuticals
•
Business Wire•Dec 09, 2024•, Lexicon Pharmaceuticals
•
GlobeNewswire•Nov 26, 2024•Lexicon Pharmaceuticals
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Frequently asked questions about Lexicon Pharmaceuticals
When was Lexicon Pharmaceuticals founded?
Lexicon Pharmaceuticals was founded in 1995.Where is Lexicon Pharmaceuticals located?
Lexicon Pharmaceuticals is located in The Woodlands, United States.When was the latest funding round of Lexicon Pharmaceuticals?
Lexicon Pharmaceuticals's latest funding round was on Aug 03, 2022.What is the annual revenue of Lexicon Pharmaceuticals?
Annual revenue of Lexicon Pharmaceuticals is $139K as on Dec 31, 2022.Our Lite Plan Awaits you - Its Free!
Sign up now to unlock full access to curated data
4M+ Companies- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Are you a Founder ?
Explore our recently published companies
- Basta - Reykjavik based, 2022 founded, Unfunded company
- Ligwood - Madison based, 2024 founded, Funding Raised company
- Plinacro - Zagreb based, 2001 founded, Funding Raised company
- Opal Therapeutics - San Francisco based, 2023 founded, Funding Raised company
- Brightwake - Nottingham based, 1979 founded, Unfunded company
- Wholesome Gift Hub - Australia based, Unfunded company
